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Abstract
Using physicochemical property-driven optimization, twelve new diarylaniline compounds
(DAANs) (7a–h, 11a–b and 12a–b) were designed and synthesized. Among them, compounds
12a–b not only showed high potency (EC50 0.96–4.92 nM) against both wild-type and drug-
resistant viral strains with the lowest fold change (FC 0.91 and 5.13), but also displayed
acceptable drug-like properties based on aqueous solubility and lipophilicity (LE > 0.3, LLE > 5,
LELP < 10). The correlations between potency and physicochemical properties of these DAAN
analogues are also described. Compounds 12a–b merit further development as potent clinical trial
candidates against AIDS.
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Non-nucleoside reverse transcriptase inhibitors (NNRTIs) with diverse structures are a key
component of antiretroviral therapy (ART) for HIV infection and AIDS, because they
exhibit high efficacy and low toxicity, as well as synergistic activity in combination with
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other anti-HIV drugs.1,2 Two new-generation NNRTIs, etravirine (TMC125, 1a) and
rilpivirine (TMC278, 1b) (Fig. 1), which were recently approved by the FDA for anti-AIDS
therapy, have much better potency and pharmacological profiles than early NNRTIs, such as
nevriapine, delavirdine, and efavirenz, and can efficiently inhibit a broad spectrum of drug-
resistant viral strains.3 However, clinical trials revealed novel resistance mutations4
conferred against drugs 1a and 1b, which are both diarylpyrimidine (DAPY) compounds,
similar to the early NNRTIs. However, these newly produced resistance mutations differ
from those affecting the early NNRTIs and from each other, suggesting that a subtle
structural difference between the drugs was sufficient to cause the occurrence of distinct
HIV mutations. This discovery underscores the necessity for developing new NNRTI drugs
with diverse scaffolds in order to provide more choices for AIDS treatment and overcome
new resistance mutants. Accordingly, a number of new-generation NNRTI agents with
diverse structures have been discovered5 and are currently undergoing preclinical and
clinical trials.
In our prior studies, several diarylanilines (DAANs) were identified as novel class of HIV-1
non-nucleoside reverse transcriptase inhibitor (NNRTI) agents with low nanomolar anti-HIV
potency against wild-type and mutated viral strains6,7, both comparable to and better than
new-generation NNRTI drugs 1a and 1b. These DAANs are shown in Figure 1 as leads 2a
and 2b. However, their poor aqueous solubility (< 1 μg/mL) resulted in very low absorption
in vivo. To improve molecular aqueous solubility, several polar groups8,9, including
carboxyl, ester, amide, hydroxyl, and CF3, were introduced at the R1 group on the central
phenyl ring, a point known to be modifiable for anti-HIV potency, while also associated
with molecular physicochemical properties. These efforts led to the discovery of
hydroxymethyl-DAAN 2c (Fig. 1) with high potency against wild-type and multi drug-
resistant viral strains (EC50 0.53 nM and 0.4 nM, respectively) and improved aqueous
solubility of 3.23 μg/mL at pH 7.4 and 20.9 μg/mL at pH 2.0. Unfortunately, 2c displayed
low oral bioavailability (F% 6.10) in pharmacokinetics assays in vivo. Herein, we have again
modified the DAAN compounds to identify potential drug candidates with balanced potency
and a desirable absorption, distribution, metabolism, and excretion (ADME) profile.
To explore the correlations between potency and physicochemical properties associated with
ADME profile, we continued to focus on the R1 substituent on the central phenyl ring. In
our newly designed series of DAAN analogues (7a–h, 11a–b, 12a–b), R1 was altered to
alkylamines or alkoxyethers with different shapes, lengths or volumes. After anti-HIV
evaluations, the new active DAAN compounds were further assessed for multiple
physicochemical properties, including aqueous solubility and lipophilicity, as estimated by
log P. Apart from aqueous solubility, lipophilicity is another major physicochemical
property that contributes to potency, affects compound solubility, determines the passive
permeability of small molecules through biological membranes, impacts drug metabolism
and pharmacokinetics, and influences adverse effects and compound-related toxicity. Most
recently, new lipophicilic parameters, i.e., lipophilic efficiency (LE), lipophilic ligand
efficiency (LLE),10 and ligand-efficiency-dependent lipophilicity (LELP),11 have been
proposed and applied in many medicinal chemistry programs12,13,14 to efficiently guide lead
optimization. Herein, the synthesis, anti-HIV potency, and assessments of multiple
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physicochemical properties of three series of new DAAN compounds (7a–h, 11a–b, 12a–b)
are reported. The results will be helpful in guiding our further lead optimization aimed at the
discovery of new clinical trial candidates as potent anti-AIDS drugs.
As shown in Scheme 1, target DAAN compounds 7a–h were prepared through a short
synthetic route, starting from commercially available 4-hydroxy-3,5-dimethylbenzonitrile
(3). The previously synthesized intermediate 5-chloro-N1-(4-cyanophenyl)-4-
methoxycarbonyl-2-nitroaniline (4)8 was coupled with 3 in the presence of potassium
carbonate in DMF under 120 °C for 6 h to afford 2,4-diarylnitrobenzene 5. By using lithium
borohydride (LiBH4), the ester group on the central phenyl ring in 5 was reduced to a
hydroxymethyl group in the key intermediate 6a. Subsequently, 6a was treated with 2,4,6-
trichloro-[1,3,5]triazine followed by nucleophilic substitution with methylamine,
cyclopropanamine, 3-aminopropan-1-ol, or 1-methyl-piperazine to produce the
corresponding compounds 6b–e, respectively, with different alkylamines at the R1 position.
Alternatively, 6a was reacted with isopropanol or methanol in the presence of bismuth
chloride (BiCl3) to afford the corresponding alkoxymethyl-DAAN compounds 6f and 6g.
Furthermore, the hydroxyl group in 6a was esterified with acetic anhydride to yield
compound 6h. Finally, the nitro group on the central ring of 6a–h was reduced via catalytic
hydrogenation in the presence of Pd-C (10%) in either EtOAc or anhydrous ethanol to
furnish new DAAN compounds 7a–h. The structures of these new DAAN compounds were
identified from proton NMR and MS spectra.15
Newly synthesized DAAN compounds 7a–h were initially evaluated against wild-type
HIV-1 (IIIB) replication in MT-2 cells in parallel with drug 1b. The data are presented in
Table 1. As expected, most new DAANs, except 7e with a bulky N-methylpiperazinyl group
at the R1 position (EC50 170 nM), exhibited low nanomolar potency with EC50 values
ranging from 1.06 to 14 nM and high selective index (SI) values of 1,142 to 114,019. The
new 7-series compounds were also evaluated against K103N/Y181C mutant-derived,
NNRTI-resistant viral strain A17. However, their potencies against the wild-type viral strain
were clearly reduced, as demonstrated by EC50 values of greater than 33 to 2,000 nM.
Based on previous SAR results,9 we then designed and synthesized two pairs of compounds
11a–b and 12a–b with a para-cyanovinyl and para-cyanoethyl (R2) group, respectively, on
the phenoxy ring (C-ring), as shown in Scheme 2. Similarly to the preparation of 7g and 7h,
methoxymethyl-DAAN 9 and acetoxymethyl-DAAN 10 were synthesized from N1-(4-
cyanophenyl)-5-(4′-cyanovinyl-2′,6′-dimethylphenoxy)-4-hydroxymethyl-2-nitroaniline
(8).9 Subsequently, the nitro group in 9 and 10 was reduced with iron powder in the
presence of NH4Cl to afford corresponding para-cyanovinyl-DAAN compounds 11a and
11b,15 respectively, while the nitro group (R1) and the conjugated double bond in the
cyanovinyl group (R2) of 9 and 10 were reduced simultaneously using catalytic
hydrogenation with Pd/C to produce para-cyanoethyl-DAAN compounds 12a and 12b.15
The two pairs of compounds, 11a–b and 12a–b, exhibited high potency against wild-type
HIV-1 replication with sub- to low nanomolar EC50 values ranging from 0.83 to 5.74 nM,
and were as or more potent than 7g and 7h, regardless of whether R2 was p-cyanovinyl or p-
cyanoethyl. More importantly, compounds 12a–b showed high potency against resistant
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viral strain A17. Specifically, cyanoethyl-DAAN 12a (EC50 2.95 nM) was more potent than
cyanovinyl-DAAN 11a (14.7 nM), while both were more potent than cyano-DAAN
compound 7g (298 nM). Similar differences in potency were observed when comparing
acetoxymethyl-DAAN compounds 12b (4.92 nM), 11b (36.5 nM), and 7h (374 nM). These
results clearly demonstrate that the R2 group on the phenoxy ring (C-ring) directly affects
molecular potency against wild-type, as well as resistant, viral strains. A cyanoethyl group,
which is more flexible due to its linearity, was more favorable than a cyanovinyl or cyano
group. Notably, highly potent 12a and 12b had low fold change (FC) between A17 and
wild-type IIIB virus with FC values of 0.91 and 5.13, respectively, much lower than that of
1b (FC 18.4) in the same assay.
Next, several physicochemical properties of newly generated DAANs (EC50 < 11 nM) (7a–
d, 7g–h, 11a–b, 12a–b) and drug 1b were assessed, and the resulting data are summarized in
Table 2. Aqueous solubility was measured by HPLC at pH 2.0 and 7.4 to reflect the
physiological conditions encountered by these compounds in stomach and plasma,
respectively. As expected, alkylamine-DAAN compounds 7b, 7c, and 7d displayed greatly
improved solubility at both pH 2.0 (263, 285, and 290 μg/mL, respectively) and pH 7.4 (159,
13, and 236 μg/mL, respectively) compared with drug 1b (pH 2.0, 74 μg/mL; pH 7.4, 0.29
μg/mL). Thus, the introduction of suitable alkylamino groups at the R1 position could
greatly improve the molecular aqueous solubility. Active compounds hydroxymethyl-
DAAN 7a (R1 = CH2OH), methoxymethyl-DAANs 7g, 11a, and 12a (R1 = CH2OMe), and
acetoxymethyl-DAANs 7h, 11b, and 12b (R1 = CH2OAc) also demonstrated improved
aqueous solubility at pH 2.0 (1.7–9.10 μg/mL), but not at pH 7.4 (< 1 μg/mL). For oral drug
candidates, better aqueous solubility at pH 2.0 is desirable to enhance absorbability in the
stomach.18 Meanwhile, we observed that all 10 new active compounds had lower melting
points than 1b. This difference might be explained by the assumption that the R1 group on
the central phenyl ring might disrupt molecular planarity and crystal packing,19 which could
also enhance molecular aqueous solubility. To estimate molecular lipophilicity, the log P
parameters of these active compounds were measured by HPLC at pH 7.4.9 The
experimental log P values fell within an acceptable range of 1.80–4.40, which is consistent
with the measured aqueous solubilities, and showed the same trend as the clog D values
predicted by ACD software. Additionally, topological polar surface area (tPSA) parameters
of all active compounds were calculated by ChemDraw Ultra 12.0 and met the criterion20 of
< 140 Å2 for potential oral drug candidates.
To estimate the possible ADME profiles and potential of our drug candidates, we focused
next on their lipophilic indices, including lipophilic efficiency (LE), lipophilic ligand
efficiency (LLE), and ligand-efficiency-dependent lipophilicity (LELP). Defined as the
difference between the negative logarithm of the measured potency (pEC50) and log P, LLE
quantifies the contribution of lipophilicity to potency, whereas LELP17 correlates with
ADME properties. Thus, compounds with a low LELP value would most likely have a high
chance of passing all ADME and safety criteria,21 while compounds with high LELP values
(typically > 10) would have a higher propensity to fail because of ADME and safety risks.
Accordingly, lipophilic parameters of the new active DAANs were calculated from their
experimental EC50 and log P values by the formulas cited at the bottom of Table 2.
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Consequently, compounds 7a, 7b, 7d, 12a, and 12b met acceptable levels for all three ligand
lipophilic-efficiency indices (LE > 0.3, LLE > 5, LELP < 10),21 while the remaining
compounds in Table 2 did not, having either LLE values lower than 5 or LELP values higher
than 10. Among the five promising compounds, 7b and 7d showed higher aqueous solubility
at different pH conditions as well as lower log P and LELP values than the other
compounds, suggesting better ADME profiles. On the other hand, the 7 series of DAANs
were not efficient against resistant viral strain A17. Compounds 12a and 12b did show more
balanced potency between the HIV-1 wild-type and resistant viral strains, as well as met
acceptable lipophilic criteria, as determined by the LE, LLE and LELP indices. However,
the aqueous solubility of both compounds was obviously lower than that of either 7b or 7d.
Thus, to avoid the risk of potential oral absorption, these results suggested that the 12a–b
pair requires additional optimization to improve aqueous solubility.
In summary, three series of new DAAN compounds (7a–h, 11a–b, and 12a–b) with
interchangeable R1 and R2 modification/optimization were successfully synthesized as part
of our ongoing anti-HIV NNRTI program. Our current physicochemical property-driven
optimization resulted in the discovery of two promising compounds, 12a and 12b, with high
potency against wild-type and drug-resistant viral strains, low nanomolar EC50 values
(0.96–4.92 nM), low fold change resistance (FC 0.91 and 5.13), and acceptable lipophilicity,
as demonstrated by meeting acceptable values for all lipophilic parameters (LE > 0.3, LLE >
5, LELP < 10; log P < 5, tPSA < 140 Å2)21, even though their aqueous solubility needs
further improvement. Optimization of the series 7 compounds revealed that (1) the presence
of an alkylamine substituent at the R1 position can greatly improve molecular aqueous
solubility (see 7b–d) without loss of antiviral potency, (2) a bulky R1 group can result in
substantially impaired antiviral activity (see 7e), and (3) introducing an H-bond acceptor or
donor at the R1 position (such as 7a–b, 7d–g) might regulate the molecular lipophilicity to
meet desired drug criteria. Our optimization efforts at the R2 position on the phenoxy ring
(C-ring) indicated that a more flexible and longer linear cyanovinyl (11 series) or,
preferably, cyanoethyl (12 series) substituent, rather than a cyano group (7 series) is crucial
for high potency against both wild-type and double-mutant drug-resistant viral strains
(compare 7g–h, 11a–b, and 12a–b). Consequently, a number of compounds from this series
are being considered for in vivo pharmacokinetic evaluation, and the results will be reported
later.
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i) K2CO3/DMF, 120 °C, 6 h; ii) LiBH4, THF/MeOH, 0 °C, 7 h; iii) 2,4,6-trichloro-
[1,3,5]triazine, DMF/CH2Cl2, rt, 4 h; iv) amine, THF, 0 °C, 0.5 h; v) ROH/BiCl3,
CH2Cl2/CCl4, rt, 4 h; (vi) Ac2O, 100 °C, Microwave, 5 min; vii) H2/Pd-C in EtOAc or
EtOH.
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i) ROH/BiCl3, CH2Cl2/CCl4, r.t. 4 h; ii) Ac2O, 100 °C, Microwave, 5 min; iii) Fe, NH4Cl,
THF/MeOH/H2O, reflux, 3 h; iv) H2/Pd-C in EtOH.
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